Trial Profile
A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 05 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 2 Feb 2009.